Clovis: 4Q Earnings Snapshot

·1 min read

BOULDER, Colo. (AP) _ Clovis Oncology Inc. (CLVS) on Tuesday reported a loss of $99 million in its fourth quarter.

The Boulder, Colorado-based company said it had a loss of $1.02 per share. Losses, adjusted for non-recurring costs, came to 74 cents per share.

The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 76 cents per share.

The biopharmaceutical company posted revenue of $43.3 million in the period, which also beat Street forecasts. Four analysts surveyed by Zacks expected $43.2 million.

For the year, the company reported that its loss narrowed to $369.2 million, or $4.38 per share. Revenue was reported as $164.5 million.

Clovis shares have risen 39% since the beginning of the year. The stock has declined 38% in the last 12 months.


This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on CLVS at